Picture of medmix AG logo

MEDX — medmix AG News Story

0.000.00%
ch flag iconLast trade - 00:00
HealthcareAdventurousMid CapNeutral

Brief: Medmix AG FY 2024 Guidance Organic Revenue Growth Of 4% To 6%,

Feb 22 (Reuters) - medmix AG  MEDX.S :
    * FY 2024 GUIDANCE: ORGANIC REVENUE GROWTH OF 4% TO 6%,
    * MANAGEMENT EXPECTS HIGHER-THAN-USUAL CAPITAL EXPENDITURE
IN 2023
(13.7% OF REVENUE) TO RETURN TO ROUGHLY 9% OF GROUP REVENUE IN
2024
    * FY EBIT CHF 16 MILLION, DOWN 18.5%
    * FY EBITDA CHF 74.4 MILLION, UP 5.2%

Further company coverage:  MEDX.S 

 ((Reuters.Briefs@thomsonreuters.com;))

Recent news on medmix AG

See all news